Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06619509 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
A Phase 2 study of Solid Tumours, sponsored by Boehringer Ingelheim.
- Active
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT06619509: Active Phase 2 study of Solid Tumours, sponsored by Boehringer Ingelheim.
NCT06619509 is a Phase 2 study of Solid Tumours that is active but no longer recruiting, run by Boehringer Ingelheim. The registered enrollment target is 90 participants, below the 136-participant average among 9 other Solid Tumours trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06619509, a Phase 2 study of Solid Tumours, is active but no longer recruiting, sponsored by Boehringer Ingelheim.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that was being developed to treat cancer. All participants take brigimadlin as tablets once every 3 weeks at the study site. At study visits, doctors check participants' health and take note of any unwanted effects. At some study visits, doctors also check the size of the tumour and whether it has spread to other parts of the body. Participants are in the study as long as they benefit from treatment and can tolerate it.
Primary Outcome
CTCAE=Common Terminology Criteria for Adverse Events
Conditions Studied
Interventions
- DRUG Brigimadlin
Study Locations (20)
Other
- Sanatorio Finochietto - CABA
- Cliniques Universitaires Saint-Luc - Brussels
- UZ Leuven - Leuven
California
- Precision NextGen Oncology - Beverly Hills
- Sarcoma Oncology Center - Santa Monica
Tennessee
- West Cancer Center & Research Institute - Germantown
- Henry-Joyce Cancer Clinic - Nashville
Connecticut
- Yale Cancer Center - New Haven
Florida
- Mayo Clinic Cancer Center - Jacksonville
Missouri
- Washington University School of Medicine - St Louis
Nebraska
- Nebraska Cancer Specialists-Omaha-69066 - Omaha
New York
- Northwell Health - Lake Success
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-12-30 |
| Est. Completion | 2030-12-30 |
| Phase | Phase 2 |
What the registry record for NCT06619509 still lists
NCT06619509 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 136-participant average among 9 other Solid Tumours trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Solid Tumours appearing as the primary indexed condition, and to 1 intervention - of which Brigimadlin is the first listed.
NCT06619509 names 20 study sites across 16 states, led by Other, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06619509 about?
NCT06619509 is a clinical study titled "A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine". This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that was...
What is the current status of trial NCT06619509?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-12-30. Estimated completion is 2030-12-30.
What conditions does trial NCT06619509 study?
This clinical trial studies the following conditions: Solid Tumours.
What interventions are being tested in trial NCT06619509?
The interventions under investigation include: Brigimadlin (DRUG).
Who is sponsoring clinical trial NCT06619509?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06619509 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumours
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06619509's enrollment target sits among peer trials
90 4th of 9 higher than 6 of 9 other Solid Tumours trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumours trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
RECRUITING · Phase 2
-
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
COMPLETED · Phase 2
-
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps
RECRUITING · Phase 1
-
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
RECRUITING · Phase 1
-
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI